As the largest and most visible organ, the skin provides opportunities to investigate immune responses in clinical studies offering insights that extend beyond our protective coat. The interplay between bench-to-bedside approaches are complemented by bedside-to-bench exchanges epitomizing translational medicine. Conversations beyond improvement in skin lesions that include the impact on patients' lives and well-being are also becoming more frequent. Just as advances in the realm of cutaneous oncology earned malignant melanoma the title of poster child for personalized cancer therapy, new advances involving psoriasis are pointing to this moniker in dermatology once again. In this commentary, the successful cycle of interactions between psoriasis patients, dermatologists, immunologists, and the pharmaceutical industry are highlighted. Lessons learned from psoriasis-based studies indicate a bright future for translational medicine based in dermatology research labs and clinics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509581 | PMC |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!